NEW YORK, July 15 (Reuters) - A Johnson & Johnson (JNJ.N) and Zeltia SA
drug for ovarian cancer should not be approved, as risks of heart and liver toxicity
its limited ability to keep the disease in check, an advisory panel to the U.S. Food
and Drug Administration said on Wednesday.
By a vote of 14-1, the panel of cancer experts recommended the agency reject the drug,
Yondelis. The FDA typically, but not always, abides by the recommendations
of its advisory panels.
Click here to read the full article from Reuters on the Ovarian Cancer National Alliance website
Every Day is a Blessing!